

24. (New) The method of claim 16, wherein the antibody binds to a 35 kD subunit of IL-12.

25. (New) The method of claim 16, wherein said antagonist is administered in a dose of from about 0.05 to about 25 mg/kg.

26. (New) The method of claim 16, wherein said antagonist is administered in a dose of from about 0.2 to about 2 mg/kg.

27. (New) The method of claim 16, wherein said antagonist is administered intravenously.

28. (New) The method of claim 16, wherein said antagonist is administered subcutaneously.

29. (New) The method of claim 16, wherein said antagonist is administered cutaneously.

30. (New) The method of claim 16, wherein said antagonist is administered in combination with other therapies for autoimmune conditions.

31. (New) The method of claim 30, wherein said therapies comprise steroidal or other anti-inflammatory therapies.

REMARKS

STATUS OF THE CLAIMS

Claims 10-31 are pending. Claims 10-15 have withdrawn as directed to nonelected subject matter. Claims 16-20 have been rejected. New claims 21-31 have been added. Support for claim 21 can be found e.g., on page 7 of the present specification. Support for claims 22-24 can be found e.g., on page 8 of the present